PMID: 7852924Feb 1, 1995Paper

Leucocyte doubling time is a useful predictor of progression-free survival in chronic lymphocytic leukaemia

Journal of Internal Medicine
U AxdorphM Björkholm

Abstract

To assess leucocyte doubling time (LDT) in relation to progression-free survival in patients with chronic lymphocytic leukaemia (CLL). In addition, to define the impact of a second LDT in both untreated and treated patients. Retrospective study of LDT in previously untreated patients with CLL. Sixty patients diagnosed over a 13-year period at a county hospital. In forty-five of the 60 patients, an LDT could be defined. These patients were included in the final analysis. LDT below and above 12 months, progression-free and overall survival. Patients in Binet stages B and C had a median LDT of 4 months as compared to 26 months in stage A patients (P < 0.01). The projected progression-free survival at 3 years was 24% in patients with an LDT of < 12 months. The corresponding figure for the remaining patients was 68% (P < 0.01). The overall 5-year survival did not differ significantly between patients with an LDT below and above 12 months, respectively. In seven untreated patients, a second LDT could be calculated which was shorter than the first recorded LDT. A second LDT was also identified in five patients post treatment that was consistently shorter than their first LDT. Measurement of LDT is a simple complement in predicting pro...Continue Reading

References

Apr 1, 1992·Mayo Clinic Proceedings·A Tefferi, R L Phyliky
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E KimbyE Löfvenberg

❮ Previous
Next ❯

Citations

Mar 23, 2010·Journal of Computer-aided Molecular Design·Richard D Cramer
May 8, 2000·Alcoholism, Clinical and Experimental Research·J C MolinaN E Spear

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.